KR20250030005A - 인간 보체 인자 c2b 에 대한 항체 및 이의 사용방법 - Google Patents

인간 보체 인자 c2b 에 대한 항체 및 이의 사용방법 Download PDF

Info

Publication number
KR20250030005A
KR20250030005A KR1020257005663A KR20257005663A KR20250030005A KR 20250030005 A KR20250030005 A KR 20250030005A KR 1020257005663 A KR1020257005663 A KR 1020257005663A KR 20257005663 A KR20257005663 A KR 20257005663A KR 20250030005 A KR20250030005 A KR 20250030005A
Authority
KR
South Korea
Prior art keywords
ser
val
leu
gly
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257005663A
Other languages
English (en)
Korean (ko)
Inventor
크리스토프 블란체토트
한스 드 하르트
Original Assignee
아르제넥스 비브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아르제넥스 비브이 filed Critical 아르제넥스 비브이
Publication of KR20250030005A publication Critical patent/KR20250030005A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Devices For Post-Treatments, Processing, Supply, Discharge, And Other Processes (AREA)
KR1020257005663A 2018-12-13 2019-12-13 인간 보체 인자 c2b 에 대한 항체 및 이의 사용방법 Pending KR20250030005A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862779102P 2018-12-13 2018-12-13
US62/779,102 2018-12-13
KR1020217021353A KR102774146B1 (ko) 2018-12-13 2019-12-13 인간 보체 인자 c2b 에 대한 항체 및 이의 사용방법
PCT/IB2019/060802 WO2020121282A1 (en) 2018-12-13 2019-12-13 Antibodies to human complement factor c2b and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217021353A Division KR102774146B1 (ko) 2018-12-13 2019-12-13 인간 보체 인자 c2b 에 대한 항체 및 이의 사용방법

Publications (1)

Publication Number Publication Date
KR20250030005A true KR20250030005A (ko) 2025-03-05

Family

ID=69143627

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257005663A Pending KR20250030005A (ko) 2018-12-13 2019-12-13 인간 보체 인자 c2b 에 대한 항체 및 이의 사용방법
KR1020217021353A Active KR102774146B1 (ko) 2018-12-13 2019-12-13 인간 보체 인자 c2b 에 대한 항체 및 이의 사용방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217021353A Active KR102774146B1 (ko) 2018-12-13 2019-12-13 인간 보체 인자 c2b 에 대한 항체 및 이의 사용방법

Country Status (20)

Country Link
US (4) US11161900B2 (https=)
EP (2) EP3893924B1 (https=)
JP (3) JP7110491B2 (https=)
KR (2) KR20250030005A (https=)
CN (2) CN113260375B (https=)
AU (3) AU2019397614B2 (https=)
BR (1) BR112021011107A2 (https=)
CA (1) CA3119655A1 (https=)
DK (1) DK3893924T3 (https=)
EA (1) EA202191658A1 (https=)
ES (1) ES2991894T3 (https=)
FI (1) FI3893924T3 (https=)
HU (1) HUE068993T2 (https=)
IL (2) IL283916B2 (https=)
LT (1) LT3893924T (https=)
MX (2) MX2021006864A (https=)
PL (1) PL3893924T3 (https=)
PT (1) PT3893924T (https=)
SG (1) SG11202105195PA (https=)
WO (1) WO2020121282A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113260375B (zh) * 2018-12-13 2024-10-01 阿尔金克斯有限公司 针对人补体因子C2b的抗体及使用方法
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
GB202407051D0 (en) 2024-05-17 2024-07-03 argenx BV Methods of treating osteoarthritis pain
WO2025257157A1 (en) 2024-06-10 2025-12-18 argenx BV Treatment or prevention of ischemia reperfusion injury in organ tranplantation
WO2025260123A1 (en) * 2024-06-17 2025-12-26 CSL Innovation Pty Ltd Anti-c2 antibodies and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998468B2 (en) 2000-03-23 2006-02-14 Tanox, Inc. Anti-C2/C2a inhibitors of complement activation
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
EP2073898A1 (en) 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
RU2474588C2 (ru) * 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010056399A1 (en) 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
SG186397A1 (en) * 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
EP2699603B1 (en) * 2011-04-19 2016-03-02 The United States of America As Represented by the Secretary Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
CA2847862C (en) 2011-09-07 2021-01-12 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
WO2014096958A1 (en) 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
DK2914291T3 (da) * 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
EP2997045A4 (en) 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
ES2904709T3 (es) 2013-05-23 2022-04-05 Broteio Pharma B V Moléculas de unión que se unen al factor C2B del complemento humano y usos de las mismas
CA2859114A1 (en) 2013-08-29 2015-02-28 International Automotive Components Group North America, Inc. Formed articles comprising carbon and natural fibers, methods of manufacture and use thereof
SI3052192T1 (sl) * 2013-10-02 2020-11-30 Medimmune, Llc Nevtralizarijoča protitelesa proti-influenci A in njihove uporabe
JP2016539919A (ja) * 2013-10-17 2016-12-22 オメロス コーポレーション Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
SG10201804960RA (en) 2013-12-12 2018-07-30 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
SI3215527T1 (sl) 2014-11-05 2025-04-30 Annexon, Inc. Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba
BR112018010279A2 (pt) 2015-11-19 2019-02-05 Abbvie Stemcentrx Llc novos anticorpos anti-emr2 e métodos de uso
EP3380518B1 (en) 2015-11-24 2026-03-25 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
WO2017132259A1 (en) 2016-01-25 2017-08-03 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch
AU2017213117A1 (en) 2016-01-27 2018-07-19 CSL Behring Lengnau AG Recombinant IgG Fc multimers
US20190151414A1 (en) 2016-05-10 2019-05-23 Annexon, Inc. Anti-complement factor c4/c4b antibodies and uses thereof
WO2018107109A1 (en) 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Novel anti-kremen2 antibodies and methods of use
CR20190468A (es) 2017-03-14 2019-12-17 Bioverativ Usa Inc Métodos para tratar enfermedades y trastornos mediados por completo
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
CN113260375B (zh) * 2018-12-13 2024-10-01 阿尔金克斯有限公司 针对人补体因子C2b的抗体及使用方法
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy

Also Published As

Publication number Publication date
US11708403B2 (en) 2023-07-25
US20200239554A1 (en) 2020-07-30
JP2024160274A (ja) 2024-11-13
PT3893924T (pt) 2024-10-09
JP2022160479A (ja) 2022-10-19
MX2021006864A (es) 2021-07-02
JP7611191B2 (ja) 2025-01-09
MX2025010337A (es) 2025-10-01
IL283916A (en) 2021-07-29
AU2025252632A1 (en) 2025-11-06
DK3893924T3 (da) 2024-11-04
CN119371526A (zh) 2025-01-28
EP4375297A2 (en) 2024-05-29
KR20210100688A (ko) 2021-08-17
HUE068993T2 (hu) 2025-02-28
ES2991894T3 (es) 2024-12-05
US20240002484A1 (en) 2024-01-04
BR112021011107A2 (pt) 2021-12-14
CA3119655A1 (en) 2020-06-18
EP3893924A1 (en) 2021-10-20
US20220267424A1 (en) 2022-08-25
US20220119509A1 (en) 2022-04-21
EP4375297A3 (en) 2024-10-30
US11591386B2 (en) 2023-02-28
KR102774146B1 (ko) 2025-02-26
SG11202105195PA (en) 2021-06-29
WO2020121282A1 (en) 2020-06-18
EA202191658A1 (ru) 2021-11-03
IL283916B1 (en) 2025-05-01
IL283916B2 (en) 2025-09-01
US11161900B2 (en) 2021-11-02
AU2022287637A1 (en) 2023-02-02
IL319975A (en) 2025-05-01
NZ776117A (en) 2024-07-26
FI3893924T3 (fi) 2024-10-04
CN113260375A (zh) 2021-08-13
LT3893924T (lt) 2024-10-10
AU2019397614A1 (en) 2021-06-03
EP3893924B1 (en) 2024-08-21
JP2022512223A (ja) 2022-02-02
JP7110491B2 (ja) 2022-08-01
AU2019397614B2 (en) 2022-09-15
AU2022287637B2 (en) 2025-07-17
PL3893924T3 (pl) 2025-01-13
CN113260375B (zh) 2024-10-01

Similar Documents

Publication Publication Date Title
KR102774146B1 (ko) 인간 보체 인자 c2b 에 대한 항체 및 이의 사용방법
US20210309728A1 (en) Fusion protein constructs for complement associated disease
AU2019398214B2 (en) Fusion protein constructs for complement associated disease
HK40121588A (zh) 针对人补体因子c2b的抗体及使用方法
CA3123004C (en) Fusion protein constructs for complement associated disease
RU2824402C2 (ru) Конструкции слитого белка для заболевания, связанного с комплементом
HK40050349B (zh) 针对人补体因子c2b的抗体及使用方法
HK40104765A (en) Antibodies to human complement factor c2b and methods of use
HK40051472B (en) Antibodies to human complement factor c2b and methods of use
HK40051472A (en) Antibodies to human complement factor c2b and methods of use
EA046598B1 (ru) Антитела против фактора c2b комплемента человека и способы применения
EA052525B1 (ru) Антитела против фактора c2b комплемента человека и способы применения
HK40050349A (en) Antibodies to human complement factor c2b and methods of use
WO2023241389A1 (zh) 针对tfpi的单克隆抗体及其用途

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250220

Application number text: 1020217021353

Filing date: 20210707

PA0201 Request for examination
PG1501 Laying open of application